Patents by Inventor Rafael Contreras-Galindo

Rafael Contreras-Galindo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150246067
    Abstract: The present invention provides compositions and methods to treat lymphoma and cancer. In particular, the present invention provides treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. The present invention further provides compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies.
    Type: Application
    Filed: March 6, 2015
    Publication date: September 3, 2015
    Inventors: Mark H. Kaplan, Rafael Contreras-Galindo, David Markovitz
  • Publication number: 20120135950
    Abstract: Compositions and methods to treat lymphoma and cancer are disclosed. In particular, the method teaches treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. Further taught are compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies.
    Type: Application
    Filed: May 21, 2010
    Publication date: May 31, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Mark H. Kaplan, Rafael Contreras-Galindo, David Markovitz
  • Publication number: 20080261216
    Abstract: The present invention relates to compositions and methods for cancer diagnosis and therapy, including but not limited to, cancer markers. In particular, the present invention relates to HERV-K(HML-2) target titers as diagnostic markers, and HERV-K(HML-2) therapeutic targets for HIV-related cancers, and other cancers.
    Type: Application
    Filed: September 10, 2007
    Publication date: October 23, 2008
    Applicant: The Regents of the University of Michigan
    Inventors: David Markovitz, Rafael Contreras-Galindo, Mark H. Kaplan, Michael H. Dosik